Modafinil: The U.S. experience

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Clinical research in the United States on the wake-promoting agent modafinil began in 1993, when Cephalon, Inc., a Pennsylvania-based biotechnology firm, licensed the rights to modafinil in the U.S. from its developer, French pharmaceutical company Laboratorie L. Lafon (1). Modafinil was approved for use in narcolepsy in France in 1992, and had been studied in other disorders of excessive sleepiness in that country, as well as for depression and “vigilance enhancement” (1,2).

Original languageEnglish (US)
Title of host publicationNarcolepsy and Hypersomnia
PublisherCRC Press
Pages571-582
Number of pages12
ISBN (Electronic)9781420019254
ISBN (Print)9780849337154
StatePublished - Jan 1 2006

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Modafinil: The U.S. experience'. Together they form a unique fingerprint.

  • Cite this

    Thorpy, M. J. (2006). Modafinil: The U.S. experience. In Narcolepsy and Hypersomnia (pp. 571-582). CRC Press.